FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106550415> ?p ?o ?g. }

• W2106550415 endingPage "2338" @default.
• W2106550415 startingPage "2328" @default.
• W2106550415 abstract "The randomized NCRN phase III ABC-02 trial provided level-A evidence for first-line chemotherapy with cisplatin and gemcitabine combination in advanced biliary cancer (ABC). This systematic literature review aims to evaluate the level of evidence for the use of second-line chemotherapy for patients with ABC in terms of overall survival (OS), response, toxicity and quality of life. Eligible studies were identified using Medline, ASCO, ESMO and the World Gastrointestinal Congress databases. Searches were last updated on 15 December 2013. Eligible studies reported survival and/or response data for patients with ABC receiving second-line systemic chemotherapy. This systematic review was registered in the PROSPERO database (No. CRD42013004205). Five hundred and fifty-eight studies were identified from the searches in Medline (n = 342), ASCO (n = 160), ESMO (n = 27) and World Gastrointestinal Congress (n = 29). Twenty-five studies were eligible: 14 phase II clinical trials, 9 retrospective analyses and 2 case reports. In total, data from 761 patients were reported with median number of patients included in each study of 22 (range 9-96). The mean OS was 7.2 months [95% confidence interval (CI) 6.2-8.2] [phase II: 6.6 (95% CI 5.1-8.1); retrospective analysis: 7.7 (95% CI 6.5-8.9)]. The mean progression-free survival (PFS), response rate (RR) and disease control rate were 3.2 months (95% CI 2.7-3.7), 7.7% (95% CI 4.6-10.9) and 49.5% (95% CI 41.4-57.7), respectively. The best correlations were between OS and PFS for all studies (r = 0.54; P = 0.01) and between OS and PFS (r = 0.61; P = 0.04) and OS and RR (r = 0.62; P = 0.03) for phase II studies, respectively. Biliary tract cancer is known to be a chemo-responsive disease. There is insufficient evidence (level C) to recommend a second-line chemotherapy schedule in ABC, although the available data suggest that a cohort of patients may benefit. Further prospective and randomized studies are needed to clarify the relative value of second-line chemotherapy in this setting." @default.
• W2106550415 created "2016-06-24" @default.
• W2106550415 creator A5003454059 @default.
• W2106550415 creator A5048763179 @default.
• W2106550415 creator A5075059160 @default.
• W2106550415 creator A5087850177 @default.
• W2106550415 date "2014-12-01" @default.
• W2106550415 modified "2023-10-18" @default.
• W2106550415 title "Second-line chemotherapy in advanced biliary cancer: a systematic review" @default.
• W2106550415 cites W1480264725 @default.
• W2106550415 cites W1883939871 @default.
• W2106550415 cites W1983753579 @default.
• W2106550415 cites W1985213644 @default.
• W2106550415 cites W1995783757 @default.
• W2106550415 cites W1997854400 @default.
• W2106550415 cites W1999642156 @default.
• W2106550415 cites W2005899744 @default.
• W2106550415 cites W2018040062 @default.
• W2106550415 cites W2020295335 @default.
• W2106550415 cites W2023155652 @default.
• W2106550415 cites W2025769688 @default.
• W2106550415 cites W2027480170 @default.
• W2106550415 cites W2028028840 @default.
• W2106550415 cites W2029996884 @default.
• W2106550415 cites W2038077024 @default.
• W2106550415 cites W2049495363 @default.
• W2106550415 cites W2062328228 @default.
• W2106550415 cites W2062628269 @default.
• W2106550415 cites W2076127799 @default.
• W2106550415 cites W2078797029 @default.
• W2106550415 cites W2084572078 @default.
• W2106550415 cites W2087336559 @default.
• W2106550415 cites W2091054988 @default.
• W2106550415 cites W2115261608 @default.
• W2106550415 cites W2125804186 @default.
• W2106550415 cites W2128889451 @default.
• W2106550415 cites W2132215313 @default.
• W2106550415 cites W2136264959 @default.
• W2106550415 cites W2146621833 @default.
• W2106550415 cites W2155139924 @default.
• W2106550415 cites W2161817637 @default.
• W2106550415 cites W2167479710 @default.
• W2106550415 cites W2168835310 @default.
• W2106550415 cites W2329913063 @default.
• W2106550415 cites W2339286023 @default.
• W2106550415 cites W4252845458 @default.
• W2106550415 cites W4294215472 @default.
• W2106550415 doi "https://doi.org/10.1093/annonc/mdu162" @default.
• W2106550415 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24769639" @default.
• W2106550415 hasPublicationYear "2014" @default.
• W2106550415 type Work @default.
• W2106550415 sameAs 2106550415 @default.
• W2106550415 citedByCount "266" @default.
• W2106550415 countsByYear W21065504152014 @default.
• W2106550415 countsByYear W21065504152015 @default.
• W2106550415 countsByYear W21065504152016 @default.
• W2106550415 countsByYear W21065504152017 @default.
• W2106550415 countsByYear W21065504152018 @default.
• W2106550415 countsByYear W21065504152019 @default.
• W2106550415 countsByYear W21065504152020 @default.
• W2106550415 countsByYear W21065504152021 @default.
• W2106550415 countsByYear W21065504152022 @default.
• W2106550415 countsByYear W21065504152023 @default.
• W2106550415 crossrefType "journal-article" @default.
• W2106550415 hasAuthorship W2106550415A5003454059 @default.
• W2106550415 hasAuthorship W2106550415A5048763179 @default.
• W2106550415 hasAuthorship W2106550415A5075059160 @default.
• W2106550415 hasAuthorship W2106550415A5087850177 @default.
• W2106550415 hasBestOaLocation W21065504151 @default.
• W2106550415 hasConcept C121608353 @default.
• W2106550415 hasConcept C126322002 @default.
• W2106550415 hasConcept C141071460 @default.
• W2106550415 hasConcept C143998085 @default.
• W2106550415 hasConcept C167135981 @default.
• W2106550415 hasConcept C17744445 @default.
• W2106550415 hasConcept C199539241 @default.
• W2106550415 hasConcept C2776694085 @default.
• W2106550415 hasConcept C2778336483 @default.
• W2106550415 hasConcept C2779473830 @default.
• W2106550415 hasConcept C2780258809 @default.
• W2106550415 hasConcept C44249647 @default.
• W2106550415 hasConcept C71924100 @default.
• W2106550415 hasConceptScore W2106550415C121608353 @default.
• W2106550415 hasConceptScore W2106550415C126322002 @default.
• W2106550415 hasConceptScore W2106550415C141071460 @default.
• W2106550415 hasConceptScore W2106550415C143998085 @default.
• W2106550415 hasConceptScore W2106550415C167135981 @default.
• W2106550415 hasConceptScore W2106550415C17744445 @default.
• W2106550415 hasConceptScore W2106550415C199539241 @default.
• W2106550415 hasConceptScore W2106550415C2776694085 @default.
• W2106550415 hasConceptScore W2106550415C2778336483 @default.
• W2106550415 hasConceptScore W2106550415C2779473830 @default.
• W2106550415 hasConceptScore W2106550415C2780258809 @default.
• W2106550415 hasConceptScore W2106550415C44249647 @default.
• W2106550415 hasConceptScore W2106550415C71924100 @default.
• W2106550415 hasFunder F4320324142 @default.
• W2106550415 hasIssue "12" @default.
• W2106550415 hasLocation W21065504151 @default.

• next